Arrowhead Pharmaceuticals Inc

ARWR

Equity

ISIN null / Valor 32193461

NASDAQ (2026-02-26)

USD 63.39+2.88%

Arrowhead Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Arrowhead Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development of innovative drugs. The company focuses on leveraging its proprietary RNA interference (RNAi) technology to silence genes that cause diseases. A specific example of their work includes the clinical study of ARO-RAGE, a therapeutic candidate aimed at treating inflammatory lung diseases. This study is designed to assess the safety, tolerability, and pharmacokinetics of ARO-RAGE in both normal healthy volunteers and participants with inflammatory lung disease, indicating Arrowhead's commitment to addressing unmet medical needs in the respiratory disease area. The study is structured in two parts, with the initial phase testing the drug on healthy volunteers and the subsequent phase on patients with the targeted condition, showcasing the company's methodical approach to drug development and its focus on RNAi technology as a basis for its therapeutic innovations.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

230%1Y

94.3%3Y

-20.4%5Y

Performance

71.7%1Y

65.3%3Y

65.6%5Y

Volatility